Teladoc Health enters its May 21 earnings date with a notable shift under the hood: short sellers have been covering meaningfully over the past month, even as the stock trades near multi-year lows at $5.95.
The short interest story is the clearest signal this week. At 15.8% of the free float, the bearish position remains substantial by any measure — but the trend has flipped. Shorts are down nearly 14% over the past month and fell another 5.9% in the past week alone, pulling from roughly 32.5 million shares in early April to 28.1 million now. That's a deliberate retreat, not noise. The ORTEX short score has correspondingly eased from a peak of 68.5 in mid-April to 64.4 today — still elevated, but off the most aggressive levels of the month. The borrow market underscores that the unwind is orderly: cost to borrow is a very modest 0.41%, down 15% over 30 days. Availability has also loosened materially — the borrow pool is nowhere near stressed. This is a short that is getting smaller by the week, not one that is pressing new highs.
Options traders are not signalling alarm either. The put/call ratio is running at 0.40, barely a half standard deviation above its 20-day average of 0.40 — essentially in line with recent norms and nowhere near the 52-week defensive peak of 1.03. Call flow is actually dominating, consistent with a market that is positioning for a potential rebound into earnings rather than bracing for a collapse. RSI14 at 59.7 sits in constructive territory, and the stock is up 16% over the past month — a material recovery off the lows even if the YTD picture, down 15%, remains uncomfortable.
The Street is cautious but not capitulating. Recent analyst activity, concentrated in the February–April window, has been a string of target cuts from across the coverage universe — JPMorgan, Citi, Oppenheimer, Barclays and others all trimmed to the $5–$7 range after the February results. The one exception: Deutsche Bank upgraded to Buy in March with an $11 target, a notable outlier that suggests at least one bellwether sees a turnaround case. More recently, Evercore ISI raised its target from $5 to $6 on April 8, maintaining its neutral view — a small but real acknowledgment that risk-reward has improved. The mean price target of $7.07 implies roughly 19% upside from current levels, though the consensus is broadly neutral rather than enthusiastic. Valuation gives bulls some comfort: EV/EBITDA is running at 4.6x and has compressed modestly over the past 30 days, while the company generates positive operating cash flow ($273 million annually) despite net losses of around $164 million. The stock trades at just 0.5x EV/revenue — not a rich multiple for a telehealth platform with $2.5 billion in revenue.
The institutional picture shows some quiet accumulation alongside the short covering. Vanguard added 1.3 million shares in Q1 to reach 11.9% of the company. Dimensional Fund Advisors added 1.2 million shares over the same period, now holding 4.2%. American Century made the most aggressive move, adding 2.6 million shares in Q1 to build a 1.7% stake. These are passive and systematic managers for the most part, but the direction of flow is worth noting — the largest institutional holders are growing positions, not trimming.
The bull case rests on operating efficiency improvements and BetterHelp stabilisation. The bear case centres on the BetterHelp segment's uncertain growth trajectory and the competitive pressure across all Teladoc's verticals. What to watch on May 21 is whether management provides any clarity on BetterHelp's pivot toward insurance revenue and whether the Primary 360 platform is adding members fast enough to justify the cost structure. Close peers AMWL gained 1.7% on the week while LFMD fell 4.1% and OPRX dropped 9.7% — telehealth sentiment remains fragmented heading into the reporting season, making TDOC's own print the more critical data point to watch.
See the live data behind this article on ORTEX.
Open TDOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
